Olmesartan Intake during Pregnancy Leading to Reversible Renal Failure and Skull Hypoplasia in a Preterm Newborn
Lata Bhat, Supriya Bisht, Kavita Khanijo
Department of Neonatology, Fortis Hospital, Noida, Uttar Pradesh, India.
Abstract

Drugs acting on renin angiotensin aldosterone system are contraindicated during pregnancy, since they cause severe fetopathic effects like renal failure, oliguria, prematurity and skeletal hypoplasia. Renal failure is progressive in majority of cases. We present a preterm infant who presented with renal failure and skull hypoplasia. Mother had taken olmesartan (angiotensin-II receptor antagonist) throughout her pregnancy. Baby had deranged renal profile and was managed conservatively. Postnatally, renal failure improved after conservative management. Her hypoplastic skull bones also showed improvement. We conclude that selection of antihypertensives during pregnancy should be rational to avoid fetotoxicity.
     Advertisements by :    Mega-CV by Aristo IndoIV by Sun Pharma
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.